CEFTIN
LOE ApproachingNDAORALFOR SUSPENSION
Approved
Jun 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEFTIN is an oral cephalosporin antibiotic suspension approved in 1994 for treating bacterial infections across multiple indications. The drug works by inhibiting bacterial cell wall synthesis, making it effective against a broad spectrum of gram-positive and gram-negative organisms. It represents a foundational antibiotic in GSK's portfolio with decades of clinical use.
LOE Approaching
Product is in late maturity phase approaching loss of exclusivity, likely requiring defensive commercialization strategies and reduced team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CEFTIN roles focus on lifecycle management, defending market share against generics, and maintaining relationships with key prescribers and health systems. Career growth is limited; this assignment typically represents a maintenance or transition role rather than a growth opportunity.
Brand Manager (Defensive)Field Sales
Worked on CEFTIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.